Innovative Microfluidic Platform Enhances Neutrophil Function Assessment in Sepsis

Sepsis, a severe condition triggered by infections and immune system dysfunction, poses significant challenges in clinical settings. At the forefront of this battle are neutrophils, a type of white blood cell crucial to the body's response to infection. However, traditional clinical methodologies have struggled to effectively isolate and analyze the functional activities of these cells simultaneously.

A groundbreaking study conducted by researchers from the Hefei Institutes of Physical Science affiliated with the Chinese Academy of Sciences and the First Affiliated Hospital of Anhui Medical University has led to the development of an advanced microfluidic platform. This innovative system is designed for the label-free sorting and functional assessment of neutrophils in patients suffering from sepsis. The findings of this research have been published in the esteemed journal, Analytical Chemistry.

The research team engineered a dual-component system that includes a cell-sorting chip (CS chip) and a deformation and chemotaxis chip (CD² chip). The CS chip efficiently extracts white blood cells from minimal blood samples (<=50 uL) while achieving high purity (>80%) and viability (>90%). Complementing this, the CD² chip evaluates neutrophil mobility by measuring deformation time (TD) and migration time (TM). Together, these components form an integrated platform that automates the processes of cell sorting and motility assessment within a rapid timeframe of just 30 minutes.

To ensure optimal performance, the researchers employed structural design optimization and COMSOL simulations to maintain gentle flow conditions, thereby preserving the integrity of the cells. Experimental validations confirmed the system's ability to create stable chemical gradients, reproducibly perform sorting operations, and deliver consistent results across different operators. Clinical tests revealed that neutrophils from sepsis patients exhibited significantly impaired mobility, evidenced by prolonged TD and TM compared to their healthy counterparts.

In addition, the research team introduced a novel Neutrophil Motility and Function Index, which effectively combines the parameters TD and TM into a singular metric. This index demonstrated impressive diagnostic accuracy and showed strong correlations with standard clinical markers, thereby enhancing its potential for clinical applications.

The newly developed microfluidic platform offers a swift, label-free, and dynamic approach to evaluating immune function, presenting promising prospects for early diagnosis, precision monitoring, and treatment optimization in sepsis management. As the medical community continues to seek innovative solutions to combat sepsis, this technology stands out as a significant advancement in the field.